EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection

Anna R. Giuliano1, Alan G. Nyitray2, Aimée R. Kreimer3, Christine M. Pierce Campbell1, Marc T. Goodman4, Staci L. Sudenga1, Joseph Monsonego5 and Silvia Franceschi6

1Department of Cancer Epidemiology, Center for Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, USA
2Center for Infectious Diseases, The University of Texas School of Public Health at Houston, Houston, TX, USA
3Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
4Department of Biomedical Science, Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
5Institute of the Cervix, Paris, France
6International Agency for Research on Cancer, Lyon, France

Human papillomaviruses (HPVs) cause cancer at multiple anatomic sites in men and women, including cervical, oropharyngeal, anal, vulvar and vaginal cancers in women and oropharyngeal, anal and penile cancers in men. In this EUROGIN 2014 roadmap, differences in HPV-related cancer and infection burden by gender and anatomic site are reviewed. The proportion of cancers attributable to HPV varies by anatomic site, with nearly 100% of cervical, 88% of anal and <50% of lower genital tract and oropharyngeal cancers attributable to HPV, depending on world region and prevalence of tobacco use. Often, mirroring cancer incidence rates, HPV prevalence and infection natural history varies by gender and anatomic site of infection. Oral HPV infection is rare and significantly differs by gender; yet, HPV-related cancer incidence at this site is several-fold higher than at either the anal canal or the penile epithelium. HPV seroprevalence is significantly higher among women compared to men, likely explaining the differences in age-specific HPV prevalence and incidence patterns observed by gender. Correspondingly, among heterosexual partners, HPV transmission appears higher from women to men. More research is needed to characterize HPV natural history at each anatomic site where HPV causes cancer in men and women, information that is critical to inform the basic science of HPV natural history and the development of future infection and cancer prevention efforts.

Over the past several decades, research focused on human papillomaviruses (HPVs) and their relationship to cervical cancer has led to major scientific discoveries, including a clear understanding of the role of HPV as a carcinogen at the cervix, use of HPV testing as part of cervical cancer prevention programs and the development, testing, licensure and implementation of two highly efficacious HPV vaccines.1 These discoveries led to notable accomplishments in countries with established HPV vaccination programs, including a significant decline in cervical HPV infection prevalence2,3 and related precancerous lesions,4-6 as well as a reduction in diagnoses of genital warts.7,8 More recently, the WHO HPV Monograph,1 published in 2007, recognized for the first time that HPV, particularly

Key words: human papillomavirus, epidemiology, gender differences, natural history, cancer

Abbreviations: HPV: human papillomavirus; HPV+: HPV positive; MSM: men who have sex with men; MSW: men who have sex with women; OPC: oropharyngeal cancer; PAF: population attributable fraction

Conflict of interest: A.R.G. is the recipient of a current investigator-initiated grant (IISP39582) from Merck and is on the Speaker’s Bureau of Merck. A.R.K. is the Co-Principal Investigator on the long-term follow-up of the Costa Rica Vaccine Trial, sponsored by the National Cancer Institute with vaccine donated by GlaxoSmithKline Biologics under a clinical trials agreement. J.M. has participated in Merck Steering Committees and on the Advisory Board of Sanofi Pasteur MSD, Gen-Probe and Roche Diagnostics. No other authors reported conflicts of interest.

Grant sponsor: The National Cancer Institute at the National Institutes of Health; Grant number: Cancer Prevention Fellowship R25T CA147832; Grant sponsor: The American Cancer Society; Grant number: Postdoctoral Fellowship PF-13-222-01

DOI: 10.1002/ijc.29082

History: Received 15 Apr 2014; Accepted 3 Jul 2014; Online 17 Jul 2014

Correspondence to: Anna R. Giuliano, Center for Infection Research in Cancer (CIRC), Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL 33612, Tel.: 813-745-6820, Fax: +813-745-1328, E-mail: Anna.Giuliano@moffitt.org

Int. J. Cancer: 00, 00–00 (2014) © 2014 UICC
HPV-16, is a cause of multiple cancers in men (penile, anal and a subset of oropharyngeal cancers [OPC]) as well as in women (cervical, vaginal, vulvar, anal and OPC). Since this publication, there has been a growing interest in understanding the epidemiology of HPV in men and infection at multiple anatomic sites in both men and women. From this more recent and limited body of research, we have observed that there are differences in HPV natural history by gender, as well as differences by anatomic site of infection. Understanding these differences remains essential to the development of efficacious interventions to prevent a multitude of HPV-related cancers afflicting both men and women.

Each year, the EUROGIN roadmap highlights cutting-edge HPV research presented at the EUROGIN Congress. The 2011 roadmap focused on HPV-related disease morbidity, as well as HPV and cancer prevention and treatment strategies, whereas the 2012 roadmap compared the epidemiology of cervical and HPV-related head and neck cancers. In the EUROGIN 2014 roadmap, we expand upon these publications by reviewing differences in HPV-related cancer and infection burden by gender and anatomic site of infection. The following review summarizes the highlights of the 2013 EUROGIN Congress entitled, *HPV at a Crossroads: 30 Years of Research and Practice* (Florence, Italy; November 3–6, 2013), specifically the session entitled, *EUROGIN 2014 Roadmap: HPV infection in men, genito-anal versus oral, convergences and divergences*.

Ideally, we would report the results from large studies focused on both genders. Unfortunately, few studies include both men and women from the same underlying population and fewer still include sampling at multiple anatomic sites. In the absence of such studies, we review studies that employed similar methodologies from comparable populations and are therefore limited in our ability to directly compare HPV across anatomic sites. For all anatomic sites other than the cervix, there is a paucity of HPV natural history publications. It is important to note that epidemiological estimates among different populations are impacted not only by the true distribution of infection and disease but also by methodological differences among studies, including population sampling strategy, sampling procedures within the anal canal, assay sensitivity and the number of genotypes detected by a given assay. Many of the limitations of the published literature highlighted here could be overcome by the addition of new HPV natural history studies that include males and females sampled at multiple anatomic sites.

**HPV-Related Cancers**

Worldwide, more HPV-related cancers are diagnosed among women compared to men, primarily owing to the large burden of cervical cancer. Among men, HPV-related cancers are rare, occurring in ~1–6/100,000 among the general population (e.g., penile, anal and OPC). However, in some countries, the incidence of OPC appears to be increasing among men. If this trend continues, gender disparities in the HPV-related cancer burden may diminish over time in countries that have implemented effective cervical cancer screening programs.

In 2008, approximately 610,000 of the 12.7 million new cancer cases were attributable to HPV (population attributable fraction [PAF]: 4.8%), with 570,000 new cancer cases diagnosed among women (PAF, 9.4%) and 39,000 cases among men (PAF, 0.6%). HPV is assumed to be responsible for 100% of cervical cancers, 88% of anal cancers, 70% of vaginal cancers, 50% of penile cancers and 43% of vulvar cancers, with the majority caused by HPV-16 or -18. The corresponding percentage for OPC is less well defined than for the other anatomic sites because of the strong association with tobacco and alcohol use. The PAF of HPV in OPC is estimated to be 26% globally, but HPV prevalence among OPC cases rises to ~50% in North America, Japan and Australia.

The proportion of total cancer cases attributable to HPV in women and men differs significantly by geographical region and economic development status of the country. Figure 1 shows PAFs of HPV in cancers among women and men globally, across nine geographic regions and three large countries. The PAF of HPV in women ranged from ≤2.5% in North America and Australia to approximately 25% in sub-Saharan Africa and India. In men, the PAF was highest...
in India (1.8%) and <1.0% in all other countries or regions.\textsuperscript{12} When comparing women and men, women have a higher incidence rate of HPV-attributable cancers than do men, and this gender difference is the greatest among less-developed countries where a higher burden of cervical cancer is coupled with a lower proportion of OPCs attributable to HPV.\textsuperscript{1,1,12}

Among HPV-attributable cancers occurring in both genders, the number of incident anal cancer cases due to HPV in 2008 was estimated to be higher in women (13,000) than men (11,000), with the proportion attributable to HPV similar among both genders.\textsuperscript{11} In contrast, the number of HPV-attributable OPGs was much greater in men (17,000) than women (4,400).\textsuperscript{11} However, these estimates were based on the assumption that the contribution of HPV to OPC etiology was similar in both genders. Case-control studies\textsuperscript{13} have suggested that the proportion of OPCs attributable to HPV is inversely correlated with population-level smoking prevalence, which varies by geographical region and gender.

**Genital HPV Infection**

Data from the studies conducted in North and Latin America indicate that genital HPV prevalence is higher in men\textsuperscript{14} than in women,\textsuperscript{15,16} and age does not appear to influence genital HPV prevalence in men\textsuperscript{14} but is strongly negatively associated with cervical HPV prevalence in women.\textsuperscript{15} The proportion of high-risk (HR) and low-risk (LR) HPV infections in women\textsuperscript{15,16} appears equivalent (HR, 14–15%; LR, 18%); however, in men, the prevalence of LR HPV (39%) is substantially higher than HR HPV (30%).\textsuperscript{14} Only a few studies have evaluated genital HPV prevalence by anatomic site. In the studies among men, HPV prevalence is highest at the penile shaft\textsuperscript{17} and lowest at the urethra.\textsuperscript{17,18} Among women, HPV prevalence is highest at the cervix and vagina and appears lower at the vulvar epithelium, likely owing to the unique vulnerability of the cervical transformation zone to infection.\textsuperscript{18}

Given the gender differences in HPV prevalence and observed age patterns, it stands to reason that the rates of HPV acquisition, as well as rates of clearance, may differ by gender. In the few studies that have evaluated HPV natural history by age among men\textsuperscript{19} and women,\textsuperscript{20,21} we note that the rate of acquiring a new genital HPV infection decreases with age in women\textsuperscript{20,21} but does not vary by age in men\textsuperscript{19} (Fig. 2a). However, once HPV is acquired, the median duration of an HPV infection appears comparable between men\textsuperscript{19} and women\textsuperscript{22} (Fig. 2b), with genital HPV-16 infections typically having a longer duration than most other HR HPV types in both men\textsuperscript{19} and women.\textsuperscript{21}

Several important questions arise from the above observations. Why is the rate of genital HPV acquisition constant over the lifespan of men but not women? Given that HPV is common at multiple anatomic sites within the genital region of men and women, why does cancer incidence differ considerably across genders and anatomic sites (e.g., ~35/100,000 for cervical cancer [unscreened population] vs. ~1/100,000 for anal, vulvar and penile cancers)? How does the local epithelial environment, such as transformation zones of the cervix and anal canal versus keratinized skin, interact with HPV to determine immune response and rate of progression to cancer?

**Anal HPV Infection**

Anal HPV has been studied more frequently in men than women although anal cancer incidence is slightly higher among women than men.\textsuperscript{23} The studies among men typically focus on HIV-positive (HPV+) individuals or men having sex with men (MSM), populations with high anal cancer incidence (5–131/100,000).\textsuperscript{24,25} Among the studies of anal HPV prevalence in HIV-negative individuals, twice as many report data among men\textsuperscript{7,26–36} than among women.\textsuperscript{37–42} Anal HPV studies among transgendered persons are rare,\textsuperscript{43} and we are aware of no studies among women who have sex with women (MSW).

Anal HPV prevalence differs by gender\textsuperscript{14} and male sexual orientation (Fig. 3).\textsuperscript{26,27,32,34,35,37,39,40,42,45–52} Comparisons of anal HPV incidence and clearance rates are more limited, given the paucity of prospective studies. Unlike anal cancer, anal HPV infection is common among women and men, including heterosexual men.\textsuperscript{32,37} A study conducted among 1,378 women of ≥18 years recruited from healthcare facilities in Hawaii estimated an anal HPV prevalence of 27%.\textsuperscript{39} The studies among women that compare cervical and anal HPV infection have shown comparable prevalence estimates at both anatomic sites.\textsuperscript{27,39} Recently, a study of 2,107 women in the Costa Rica Vaccine Trial observed a cervical HPV prevalence of 37% and an anal HPV prevalence of 32%.\textsuperscript{37} As it has been shown in most studies of genital HPV, a decline in anal HPV prevalence with increasing age has been observed in women\textsuperscript{38,39} but not in MSW.\textsuperscript{53} Anal HPV prevalence is typically higher among women with HPV-related cervical disease and women at increased risk for HIV.\textsuperscript{40,54–58}

Among men, anal HPV prevalence varies widely by sexual practice. The studies of anal HPV among MSW observe a prevalence of approximately 12%, nearly half that observed among women. In contrast, studies among MSM demonstrate a higher prevalence, with ≥50% of HIV-negative MSM having any type of anal HPV infection, depending on the population sample.\textsuperscript{24,27,28} A 2012 meta-analysis estimated the prevalence of HPV-16 infection to be 12.5% at the anal canal among HIV-negative MSM.\textsuperscript{24} In general, anal HPV prevalence among MSM is twice that among women, whereas anal HPV prevalence among women is twice that among MSW. A large study of urban MSM in the United States at HR for HIV observed a stable anal HPV prevalence across age groups\textsuperscript{27}; however, a smaller study that enrolled MSM regardless of their risk for HIV observed a declining anal HPV prevalence with age. The co-occurrence of genital HPV and anal HPV is common among MSW which, as with women, presents the possibility that sexual and/or nonsexual behaviors commonly transfer the virus between the male genitals and the anal canal.\textsuperscript{32,33,39}

There are few prospective studies of anal HPV infection among women or men.\textsuperscript{43} The 12-month cumulative incidence of anal HPV in 431 clinic-based women in Hawaii was
approximately 24% for HR HPV types and 14% for LR HPV types. Women aged ≥ 45 years had a 57% lower risk of acquisition compared to women under age 25; however, persistence of anal HPV did not differ by age. One study estimated a several-fold lower anal HPV incidence among MSW than that reported among women, whereas incidence of anal HPV among HIV-negative MSM was high, with approximately 40% of MSM acquiring an anal HPV genotype annually. Although the data are limited, two studies, approximately 75% of MSM had persistent HPV-16 infection for at least 6 months. Conversely, one of these studies observed that out of 21 MSW with anal HPV-16 infection at baseline, none retained the same HPV genotype at the 6-month follow-up visit. As HPV-16 and −18 are responsible for the majority of anal cancers, these HPV-16 persistence data among MSW and MSM help to explain the striking difference in anal cancer incidence between the two groups. Adequately powered prospective studies are needed to fill gaps in knowledge relative to gender differences in anal HPV natural history.

**Oral HPV Infection**

Oral HPV natural history appears to vary significantly by gender. In a recently completed population-based study conducted in the United States, the age-specific pattern of oral HPV prevalence was similar among men and women, with peak prevalence observed among individuals aged 30–34 years and again among those aged 60–64 years. However, the absolute prevalence of oral HPV (any genotype) was considerably higher in men compared to women (10.1%; 95% confidence interval [CI]: 8.3–12.3% vs. 3.6% [95% CI: 2.6–5.0%], p < 0.001; respectively). In this nationally representative sample, factors independently associated with oral HPV prevalence beyond male gender included older age, higher number of lifetime sexual partners and current cigarette use (>10 cigarettes per day). In most studies conducted among healthy individuals, oral HPV-16 prevalence is low, typically between 0.5 and 1%, and is consistently found to be substantially lower than what is typically observed at the anogenital region for both men and women. Given the rarity of oral HPV infection, large sample sizes are needed to evaluate oral HPV natural history and to

---

**Figure 2. (a) Genital HPV incidence among men and women by age. (b) Duration of genital HPV infections among men and women by age (modified from Refs. 19,21,22).**
precisely estimate rates of acquisition and clearance. To date, there have been only seven studies that report incidence and persistence of oral HPV,\textsuperscript{67–73} and few included both men and women.\textsuperscript{67,71,72} To date, the largest study\textsuperscript{71} to include both genders focused on 1,000 young adults from a university setting. Oral gargle specimens were collected at baseline and 3 months later. Overall, oral HPV prevalence was rare and higher in men than women (3.2\textsuperscript{vs} 1.7\%, respectively) as it has been consistently shown. For both genders combined, the crude oral HPV incidence rate was 5.7 per 1,000 person-months. Gender was not identified as a significant risk factor for oral HPV acquisition in our study.

The largest prospective study conducted to date to evaluate oral HPV natural history is the HPV Infection in Men (HIM) Study,\textsuperscript{70} a multinational cohort of >4,000 men aged 18–70 years.\textsuperscript{14,19,74} In the oral subcohort (\(N = 1,626\) men), 4.4\% (95\% CI: 3.5–5.6) of men acquired a new oral HPV infection of any type, 1.7\% (95\% CI: 1.2–2.5) acquired a new oral HR HPV infection and 0.6\% (95\% CI: 0.3–1.1) acquired a new oral HPV-16 infection. In a follow-up report of these men,\textsuperscript{75} oral HPV-16 infections tended to persist beyond 1 year and persistence increased significantly with age, potentially explaining the higher prevalence of oral HPV observed at older ages.

![Figure 3. Mean prevalence of selected anal HPV groups and HPV-16 among HIV-negative men and women in studies with sample sizes of \(\geq 100\) persons (modified from Refs. 26,27,32,34,35,37,39,42,45–52).](image)

The rate of oral HPV incidence in men is an order of magnitude lower than that of genital HPV infection (Table 1).\textsuperscript{19,70} Similar findings for oral HPV in women are unavailable as there have not been sufficiently large natural history studies conducted to date. It is currently unknown about the reason why oral HPV prevalence is lower in women compared to men though several hypotheses exist: (i) men have more sexual partners, thus, more opportunity for HPV exposure; (ii) transmission of infection is more efficient when performing oral sex on infected female genitals (i.e., a mucosal surface) compared to transmission when performing oral sex on the keratinized epithelium of a penis and (iii) women, who have some level of systemic immunity from cervical HPV infection,\textsuperscript{76} may be protected against oral HPV infection, whereas no such protection has been observed in men.\textsuperscript{77}

### HPV Serology

As presented above, HPV infections can occur at multiple anatomic sites; once infected, most individuals are able to naturally clear the infection through an immune response. In total, 9–24 months after initial HPV infection, a proportion of individuals develop detectable antibodies to the specific HPV type.\textsuperscript{78,79} There are several valid laboratory methods that quantify IgG antibodies to type-specific HPV virus-like particles,\textsuperscript{80} and determining seropositivity is dependent on the assay used and the comparison population. Therefore, comparing results between serological assays is difficult owing to the use of different cutoff values and lack of an international reference population.\textsuperscript{80}

Consistently, women demonstrate a higher HPV-16 seroprevalence than men, regardless of the population studied (Fig. 4).\textsuperscript{81–89} Despite a higher genital and oral HPV DNA prevalence observed in men, HPV 6 and 18 seroprevalence is also significantly higher among women compared to men, regardless of the geographic region or risk level of the populations.\textsuperscript{81–86,90}

<table>
<thead>
<tr>
<th>Prevalence (%)</th>
<th>Incidence rate per 1,000 person-months</th>
<th>Median time to clearance (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genital HPV\textsuperscript{14,19}</td>
<td>50.4</td>
<td>38.4</td>
</tr>
<tr>
<td>Anal HPV\textsuperscript{1} (Refs. 32,62)</td>
<td>12.0</td>
<td>8.1</td>
</tr>
<tr>
<td>Oral HPV\textsuperscript{70,74}</td>
<td>4.0</td>
<td>5.6</td>
</tr>
</tbody>
</table>

\textsuperscript{1}Heterosexual men.
However, HPV 11 seroprevalence does not appear to differ by gender in population-based studies published to date.81,84,85,91 Given the differences in HPV seroprevalence by gender, differences in the rates of seroconversion after HPV infection among men and women are of interest. It appears that only a subset of men and women with HPV infection mount a detectable antibody response, with a higher percentage of women seroconverting to HPV-16 and -18 compared to men.79,92,93 In one study conducted among young women,92 58–67% developed a detectable HPV-16 antibody within 2 years after an incident HPV-16 infection, compared to only 7–11% of men.79,93 Similarly, women were significantly more likely to seroconvert within 2 years after an incident HPV 18 infection compared to men (54 vs. 2%, respectively).79,94 However, seroconversion after an incident HPV 6 infection was common among women (69%) and men (51%).79,94

The protection conferred by antibodies generated in response to natural infection against future HPV infections differs between men and women. Three prospective studies of women76,95,96 assessed the role of antibodies in protection against future HPV infections. In the Guanacaste cohort,96 no association was observed between serum antibodies above the cutoff level and protection against future HPV infections, whereas a study in college-aged women65 and the placebo arm of the Costa Rica vaccine trial76 both describe a 50% reduction in risk against future HPV-16 infections among unvaccinated women who had high antibody titers for HPV-16 compared to HPV-16 seronegative women. In the prospective HIM Study,72 HPV-16 seropositivity in unvaccinated men was not associated with reduced risk of future HPV-16 infection, regardless of the level of antibody.

**Heterosexual HPV Transmission**

HPV transmission dynamics are dependent on both viral and host factors, defined by susceptibility (e.g., HPV serostatus among women), contact rate per unit time, transmission probability and duration of infectiousness.75 In a recent meta-analysis of 30 HPV type-specific concordance studies98 26% of 2,972 couples were infected with one or more of the same genital HPV types, underscoring the high transmissibility of HPV. Concordance was even higher (63%) when the analysis was restricted to couples that were both genital HPV+. However, the percentage of men with the same HPV type as their HPV+ female sexual partner (36%) was lower than the percentage of women with the same HPV type as their HPV+ male sexual partner (55%). These findings suggest that the epithelial cells of the penile skin are more resistant to HPV infection than the cervical epithelium, the duration of HPV infection is shorter in

<table>
<thead>
<tr>
<th>Reference</th>
<th>Population</th>
<th>Heterosexual couples (N)</th>
<th>Incidence per 100 person-months (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hernandez et al.59</td>
<td>Unites States</td>
<td>25</td>
<td>4.5 (1.5–9.3) 27.8 (19.0–38.3)</td>
</tr>
<tr>
<td>Burchell et al.99</td>
<td>Canada</td>
<td>179</td>
<td>3.5 (2.7–4.5) 4.0 (3.0–5.5)</td>
</tr>
<tr>
<td>Mbulawa et al.100</td>
<td>South Africa</td>
<td>486</td>
<td>1.2 (0.8–1.7) 2.8 (2.0–3.9)</td>
</tr>
<tr>
<td>Widdice et al.102</td>
<td>United States</td>
<td>25</td>
<td>9.2 (1.1–33.3) 21.4 (7.8–46.5)</td>
</tr>
<tr>
<td>Nyitray et al.101</td>
<td>United States</td>
<td>65</td>
<td>0.7 (0.4–1.4) 1.2 (0.7–2.0)</td>
</tr>
</tbody>
</table>
men than in women and/or HPV testing is less sensitive in men than in women.97,98

Five longitudinal heterosexual transmission studies with various follow-up times and sampling frequencies have been conducted, each of which recruited initially HPV-discordant couples.59,99–102 In all studies, the incidence of transmission from men to women was lower than the incidence from women to men, supporting the notion that men acquire more transient infections than women (Table 2).19 In one study,103 the per-partnership probability was estimated to be 0.05–0.28 for male-to-female transmission and 0.19–0.81 for female-to-male transmission, highlighting the efficiency of heterosexual HPV transmission. These ranges are understandably correlated with the frequency of HPV testing among the couples, with much higher estimates associated with greater sampling frequency. Another study102 found the highest rates of genital HPV transmission within 24 hr of sexual intercourse, indicating that contamination from the partner may inflate transmission probabilities. Although genital–genital contact appears to account for the majority of heterosexual HPV transmission events, other modes of transmission are possible, including anal–genital, oral–genital and manual–genital contact, sex toys and perhaps autoinoculation (i.e., transmission between the genitals, anal canal, oral cavity or hands of the same individual).

HPV appears to be frequently detected at the anal canal and on the hands.59,102 As such, HPV transmission through nonpenetrative sexual contact, such as fingers to genitals or anal canal, has been observed,59,102,104 but the majority of HPV+ fingertip specimens likely represent deposition of DNA from genitals rather than true infection. Some anal HPV infections in women may occur as a result of viral shedding of cervical or vaginal HPV infections in vaginal discharge. Indeed, anal and cervical HPV infections occur consecutively,106 suggesting that the vagina and, to a lesser extent, the anal canal, serve as reservoirs for HPV infection at the other anatomical sites. Cross-sectional analyses demonstrating type-specific concordance of HPV infection of the genitals and anal canal among heterosexual men highlight the complexity of determining true sources and targets of viral transmission.53 Understanding heterosexual HPV transmission is further complicated by the possibility of autoinoculation.59 Enhanced understanding of HPV transmission dynamics will assist in promulgating more efficient strategies for the prevention and control of HPV-related cancers.

Conclusions
HPV causes cancer in both men and women. The HPV-related cancer burden remains higher in women than men, even in countries that have effective cervical cancer screening programs. Emerging data indicate that HPV infection appears to vary significantly by gender as well as across anatomic sites. This variation in HPV prevalence may explain the differences in cancer incidence rates observed by gender in some cases (e.g., OPC and oral HPV infection are both higher in men than in women); however, in other cases, cancer rates are remarkably similar among men and women (e.g., anal cancer) despite large differences in HPV prevalence. In addition, within a population, emerging data demonstrate that HPV prevalence varies markedly by anatomic site evaluated, indicating that for the same sexual exposure, susceptibility to infection varies by epithelium. Adding to the complexity of the viral–host interaction are differences in the adaptive immune response to natural HPV infection observed between men and women.

In summary: (i) HPV infection patterns differ by anatomic site (higher prevalence in the genitals vs. oral region); (ii) HPV infection and clearance rates differ by gender; (iii) transmission rates differ by gender, with higher female-to-male compared to male-to-female transmission and (iv) immune response to HPV differs by anatomic site of infection and is stronger and more protective against reinfection in women than men. Altogether, these observations lead us to conclude that more research is needed to fully characterize HPV natural history at each of the anatomic sites where HPV causes cancer in men and women, which is critical to inform the basic science of HPV natural history and the development of future infection and cancer prevention efforts.

Acknowledgements
The authors thank the EUROGIN 2013 conference organizers, Mr. Jerome Vignat for unpublished data on HPV-attributable fractions, and Dr. Beibei Lu for providing the serology figure. Our study was supported, in part, by the National Cancer Institute at the National Institutes of Health (Cancer Prevention Fellowship R25T CA147832 to S.L.S.) and the American Cancer Society (Postdoctoral Fellowship PF-13-222-01-MPC to C.M.P.C.).

References